ImStem Biotechnology Appoints CNS and Rare Disease Veteran Rami Levin as Managing Director

FARMINGTON, CT, USA, September 1, 2022 / — ImStem Biotechnology, Inc., a clinical-stage biotechnology company focused on regenerative stem cell therapies to treat serious diseases with high unmet needs, today announced the appointment of Rami Levin to position of Chairman and Chief Executive Officer and member of its Board of Directors.

Mr. Levin is a seasoned biotechnology leader with over 26 years of experience in central nervous system disorders and rare diseases. Mr. Levin most recently served as President and CEO of Saniona, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for patients with rare diseases. While at Saniona, he built the corporate headquarters and hired the management team in the United States and raised significant capital to advance its clinical programs. Prior to joining Saniona, Mr. Levin was President of Sobi Inc., the North American subsidiary of Sobi, where he built and led the organization from its inception to a team of over 300 employees and generated over half a billion USD in annual revenue. Mr. Levin’s experience in mergers and acquisitions has resulted in the successful acquisitions of Gamifant®, the first FDA-approved treatment for primary hemophagocytic lymphohistiocytosis (pHLH), and Synagis, the only FDA-approved prophylaxis for respiratory syncytial virus (RSV). Prior to Sobi Inc., Mr. Levin held commercial leadership positions of increasing strategic importance for 18 years at Merck Serono and Schering AG.

We are very pleased to welcome Rami to ImStem as CEO, a role to which he brings years of experience highly relevant to the continued development of the business. Rami has a proven track record in many areas critical to ImStem including CNS indications, multiple sclerosis, rare diseases, fundraising and organization building. Rami is an ideal candidate for ImStem,” said Michael Men, Chairman of the Board of ImStem Biotechnology, Inc.

“I am honored to take on this extremely exciting role at ImStem and to oversee the next stage of the company’s development,” said Rami Levin. “This is an important moment in the growth of ImStem, as it aims to revolutionize the way serious diseases with significant unmet need are potentially treated with regenerative and cellular therapies.”

Mr. Levin earned his MBA from Recanati Business School at Tel Aviv University in Israel, majoring in International Marketing and holds a BSc in Biology from Tel Aviv University.

About Imstem Biotechnology, Inc.:
ImStem Biotechnology, Inc. aspires to revolutionize the way serious diseases with high unmet needs are potentially treated with a new generation of regenerative and cellular therapies. Pioneering research has led to proprietary cutting-edge pluripotent stem cell technology, enabling large-scale manufacturing of ready-to-use allogeneic stem cell-derived products, differentiating from the typical challenges imposed by autologous adult cell therapy products. The company’s mission is to advance the science and understanding of regenerative cell therapies based on human pluripotent stem cells through new and creative pathways of development and to address unmet medical needs in serious diseases. Its development strategy focuses on neurological, autoimmune, degenerative and rare orphan diseases.

For more information visit:

Investor Relations
+1 860-281-7836
write to us here

Comments are closed.